ClinicalTrials.gg
RecruitingNCT07005024DOACUpdated Feb 5, 2026

DOAC - Dosing Options in AntiCoagulation Prophylaxis

A Phase 3 interventional study of Apixaban 2.5 mg twice daily and Apixaban 5 mg once daily in Cancer and VTE (Venous Thromboembolism), sponsored by University of Vermont. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by University of Vermont · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
996
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience.

This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of blood clots and death in cancer patients who are at moderate risk for VTE. The study focuses on people who have a "Khorana score" of 2, which puts them at intermediate risk for developing blood clots.

The study will include approximately 996 participants with solid tumors or lymphoma who are starting or recently started cancer-directed therapy. Participants will be randomly assigned to one of three groups:

Group 1: Apixaban 2.5 mg twice a day (standard prophylactic dose)

Group 2: Apixaban 5 mg once a day (an alternative, more convenient dose)

Group 3: No anticoagulant (standard care)

Participants will take the assigned treatment (if applicable) for 6 months. Researchers will monitor whether participants develop blood clots, experience serious bleeding events, or die from any cause during the study period.

By comparing these three groups, the researchers hope to learn whether a once-daily dose of apixaban can work as well as the standard twice-daily dose, and whether either dosing strategy is better than no anticoagulation at all. If successful, the study may help increase the safe use of VTE prevention in cancer patients and improve overall outcomes, especially in patients at intermediate risk.

This is a pragmatic trial, meaning it is designed to fit into real-world clinical practice with minimal extra procedures. The study drug is not provided by the sponsor and will be prescribed and filled through usual care channels. Participants and their doctors will decide whether to continue the medication after the study ends.

Read the detailed description

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in ambulatory patients with cancer, particularly within the first several months after initiating cancer-directed therapy (CDT). The Khorana Risk Score (KRS) is a validated tool used to identify cancer patients at increased risk of VTE. While patients with a KRS ≥ 2 are eligible for VTE prophylaxis under current clinical guidelines, there remains a major gap between these recommendations and clinical practice. Implementation of prophylaxis is low due to concerns about bleeding, uncertainty regarding net clinical benefit, and challenges with medication adherence-particularly with twice-daily dosing regimens.

Apixaban, a direct oral anticoagulant (DOAC), is FDA-approved and supported by NCCN and ASH guidelines for VTE prevention in high-risk ambulatory cancer patients. The AVERT trial demonstrated that apixaban 2.5 mg twice daily significantly reduced VTE events in cancer patients with a KRS ≥ 2 but increased the risk of major bleeding. However, this dosing strategy remains underutilized. The possibility of once-daily dosing with apixaban, which could improve adherence and acceptance among patients and physicians, has not been adequately studied in this population.

This single-center, phase III, open-label, pragmatic randomized clinical trial will evaluate two dosing strategies of apixaban for VTE prevention in cancer outpatients with a KRS of 2. A total of 996 participants will be randomized 1:1:1 to receive:

Arm 1: Apixaban 2.5 mg twice daily

Arm 2: Apixaban 5 mg once daily

Arm 3: No anticoagulant prophylaxis (standard care)

The primary objective is to compare the incidence of VTE across these arms over a 6-month treatment period. Secondary objectives include comparisons of all-cause mortality and rates of clinically significant bleeding events (CTCAE grade ≥ 3).

Participants must have a solid tumor or lymphoma and be initiating or recently initiated on CDT. Those with recent VTE, active anticoagulation for another indication, hematologic malignancies (e.g., acute leukemia, myeloma), or high bleeding risk are excluded.

Randomization occurs after eligibility is confirmed via chart review and informed consent is obtained. In line with a pragmatic trial design, there are no mandated study visits beyond a brief 2-month patient-reported outcomes (PRO) check-in. All other data, including VTE events, mortality, bleeding, and adherence, are captured via electronic health record abstraction and PRO questionnaires.

Drug is not provided as part of the study; apixaban will be prescribed as part of usual clinical care and filled through the participant's pharmacy. Participants who are unable to obtain the drug due to insurance or financial barriers will still be followed in their assigned study arm per intent-to-treat principles.

The study will use a formal interim analysis following the O'Brien and Fleming approach, with stopping rules for futility and efficacy. Final analyses will compare VTE incidence and other endpoints using chi-square tests and Kaplan-Meier survival analysis, as appropriate.

This trial is designed to generate real-world evidence to inform anticoagulant prescribing practices in cancer outpatients at intermediate risk for VTE. Results may support broader, more personalized adoption of thromboprophylaxis strategies that balance effectiveness, safety, and feasibility.

02

Conditions studied

  • Cancer
  • VTE (Venous Thromboembolism)

Keywords

  • Apixaban
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 996 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Vermont is the lead sponsor of 221 studies on the registry; 27 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosed with an active solid tumor or lymphoma
  • Starting a new systemic cancer treatment or changing cancer treatment
  • Khorana Risk Score of 2 (calculated based on lab and clinical data at treatment initiation)
  • Not currently receiving therapeutic anticoagulation
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or high risk of bleeding (e.g., recent major surgery, CNS tumors with hemorrhagic risk)
  • Known to apixaban (e.g., allergy, severe liver disease, dual strong and P-gp inhibitors)
  • Current therapeutic-dose anticoagulation for VTE or atrial fibrillation
  • count \< 50,000/µL
  • \< 25 mL/min
  • \< 3 months
  • Pregnant or breastfeeding
  • Inability to comply with study procedures
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
996 participants (estimated)

Study arms

  • Experimental
    Arm 1: Apixaban 2.5 mg Twice Daily Prophylaxis

    Participants in this arm will receive apixaban 2.5 mg by mouth twice daily (BID) for 6 months. This is the guideline-supported prophylactic dose for VTE prevention in high-risk ambulatory cancer patients.

    Drug: Apixaban 2.5 mg twice daily

  • Experimental
    Arm 2 Title: Apixaban 5 mg Once Daily Prophylaxis

    Participants in this arm will receive apixaban 5 mg by mouth once daily for 6 months. This alternative dosing schedule is being tested for its potential to improve adherence and maintain VTE protection in moderately high-risk cancer outpatients.

    Drug: Apixaban 5 mg once daily

  • Active comparator
    No Anticoagulation (Control)

    Participants in this arm will not receive any anticoagulant prophylaxis. This approach reflects current standard-of-care practice for many patients with a Khorana Risk Score of 2, where anticoagulation is not routinely prescribed.

    Drug: No anticoagulation

Interventions

  • DrugApixabanStudies of ApixabanApixaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apixaban, a direct oral anticoagulant (DOAC), will be administered at a prophylactic dose of 2.5 mg by mouth twice daily for 6 months. This dose is guideline-recommended for VTE prevention in high-risk ambulatory cancer patients. Participants will continue their cancer-directed therapy during this time. No study-mandated visits or labs are required beyond standard care.

  • DrugApixabanStudies of ApixabanApixaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apixaban will be administered at 5 mg by mouth once daily for 6 months. This alternative prophylactic schedule is being studied to assess its effectiveness and adherence in patients with a Khorana Risk Score of 2. Participants will continue their usual cancer treatment. This arm evaluates a simplified dosing strategy in a real-world, pragmatic design.

  • DrugNo anticoagulation

    Participants randomized to this arm will not receive apixaban or any other anticoagulant for VTE prevention. This reflects current standard care for many cancer outpatients with moderate risk (Khorana Score = 2). Outcomes will be monitored through routine care and medical record abstraction.

06

What researchers measure

Primary outcomes

  1. Incidence of VTE in Participants Receiving Apixaban 2.5 mg Twice Daily vs No Anticoagulation

    This outcome compares the incidence of venous thromboembolism (VTE) - including deep vein thrombosis, pulmonary embolism, and other clinically relevant thromboses - between participants receiving apixaban 2.5 mg BID and those receiving no anticoagulation prophylaxis. Events will be identified through clinical care and confirmed via chart review. Both symptomatic and incidental VTEs will be included.

    Time frame: 6 months

  2. Incidence of VTE in Participants Receiving Apixaban 5 mg Once Daily vs No Anticoagulation

    This outcome compares the incidence of venous thromboembolism (VTE) between participants randomized to apixaban 5 mg once daily and those receiving no anticoagulation. VTEs may include DVT, PE, or other thromboses, whether symptomatic or incidental. Events will be confirmed through medical record review. The goal is to determine whether this simplified dosing schedule provides effective VTE prevention in cancer patients with Khorana Risk Score of 2.

    Time frame: 6 months

Secondary outcomes

  1. All-Cause Mortality in Participants Receiving Apixaban 2.5 mg Twice Daily vs No Anticoagulation

    This outcome compares all-cause mortality at 6 months between participants randomized to apixaban 2.5 mg twice daily and those receiving no anticoagulation prophylaxis. Vital status will be determined through medical record review and/or survival follow-up.

    Time frame: 6 months

  2. All-Cause Mortality in Participants Receiving Apixaban 5 mg Once Daily vs No Anticoagulation

    This outcome compares all-cause mortality at 6 months between participants receiving apixaban 5 mg once daily and those receiving no anticoagulation. Vital status will be assessed using clinical follow-up and medical record review.

    Time frame: 6 months

  3. Incidence of Clinically Significant Bleeding Events (CTCAE Grade ≥3)

    This outcome evaluates the incidence of clinically significant bleeding events (CTCAE v5.0 Grade ≥3) in participants randomized to apixaban 2.5 mg twice daily, 5 mg once daily, or no anticoagulation. Events include bleeding requiring hospitalization, transfusion, or occurring at critical sites (e.g., intracranial, GI). Bleeding events will be identified through routine clinical care and confirmed via chart review.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Anonymized patient related data will be incorporated into publications and will be made available to other investigators at reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2035, 118 months after the start.

Of 83 non-industry phase 3 interventional studies under Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 96. This study's planned 118 months is above that.

Counting every sponsor, half of 203 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 4, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Aug 2035
CompletionEst.
Aug 2035
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07005024
Responsible party
Steven Ades (Medical Director, University of Vermont) — Principal investigator
First posted
Jun 4, 2025
Start date
Oct 17, 2025
Primary completion
Aug 2035 (estimated)
Completion
Aug 2035 (estimated)
Last update
Feb 5, 2026

Study contacts

Steven Ades, MD, MSc
Contact
steven.ades@med.uvm.edu
1 (802) 656-2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion